Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity

MT Newswires Live

03/19

Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.

The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.

The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620941432"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620941432\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620941432?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 09:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620941432","market":"nz","top_or_hot":-1,"title":"Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity","media":"MT Newswires Live","content":"<html><body><p> Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.</p><p>The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.</p><p>The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syntara Receives Nearly AU$2 Million Milestone Payment from UK Charity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyntara Receives Nearly AU$2 Million Milestone Payment from UK Charity\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-19 09:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.</p><p>The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.</p><p>The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2620941432","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620941432","pubTimestamp":1773883147,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Syntara  received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","SNT.AU":"Syntara Ltd"},"translate_title":"Syntara收到英国慈善机构近200万澳元的里程碑付款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNT.AU":1},"content_text":"Syntara (ASX:SNT) received a milestone payment of about AU$1.7 million from Parkinson's UK following the dosing of the final patient in its second-phase clinical trial of SNT-4728, a potential treatment targeting neuroinflammation linked with early-stage Parkinson's disease, according to a Thursday filing with the Australian bourse.The trial is evaluating SNT-4728 in individuals diagnosed with isolated rapid eye movement sleep behavior disorder, one of the strongest early indicators of future Parkinson's disease and related neurodegenerative disorders, the filing said.The company will be eligible to receive a further AU$450,000 upon completion of the project, per the filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}